Loading…
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $239M | $-37M | $-80M | $-40M | -23.4% | -23.7% | 298.1% |
| 2024 | $314M | $-6M | $-20M | $-8M | -5.1% | -2.6% | -194.7% |
| 2023 | $322M | $33M | $21M | $-4M | 5.5% | 13.4% | -46.2% |
| 2022 | $284M | $48M | $40M | $18M | 11.8% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 284.39 | 322.42 | 313.90 | 239.44 |
| Cost Of Revenue | - | 61.01 | 69.76 | 74.32 | 57.02 |
| Gross Profit | - | 223.38 | 252.65 | 239.58 | 182.42 |
| Operating Expense | - | 179.58 | 224.55 | 252.19 | 228.37 |
| Operating Income | - | 43.80 | 28.10 | -12.61 | -45.95 |
| EBITDA | - | 48.31 | 33.22 | -5.72 | -37.22 |
| EBIT | - | 43.80 | 28.10 | -12.61 | -45.95 |
| Pretax Income | - | 45.55 | 33.70 | -9.05 | -82.26 |
| Tax Provision | - | 5.89 | 12.35 | 11.16 | -1.82 |
| Net Income | - | 39.66 | 21.35 | -20.21 | -80.45 |
| Net Income Common Stockholders | - | 39.66 | 21.35 | -20.21 | -80.45 |
| Total Expenses | - | 240.59 | 294.32 | 326.51 | 285.39 |
| Interest Income | - | 2.45 | 6.99 | 5.91 | 4.59 |
| Research And Development | - | 35.98 | 40.48 | 45.32 | 40.06 |
| Selling General And Administration | - | 143.60 | 184.08 | 206.88 | 188.31 |
| Normalized EBITDA | - | 50.02 | 35.13 | -2.04 | 5.95 |
| Normalized Income | - | 41.15 | 22.56 | -17.30 | -38.23 |
| Market Cap | 1,270.99 | 1,270.99 | 1,270.99 | 1,270.99 | 1,270.99 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| STAAR Surgical Companythis co. | STAA | - | -15.80 | 3.69 | -23.4% | -31.07 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $68M | - | 8.45 | -280.5% | - |
| LENSAR, Inc. | LNSR | $65M | - | -2.48 | 131.7% | -3.17 |
| Pulmonx Corporation | LUNG | $51M | - | 0.92 | -99.8% | -0.71 |
| Accuray Incorporated | ARAY | $50M | - |
| - |
| - |
| - |
| - |
| - |
| 0.94 |
| -2.0% |
| -107.66 |
| INmune Bio Inc. | INMB | $35M | - | 1.50 | -195.3% | -0.38 |
| Myomo, Inc. | MYO | $31M | - | 2.68 | -136.6% | -2.33 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | - | 1.37 | -87.0% | 0.07 |
| Tevogen Bio Holdings Inc. | TVGN | $27M | - | -1.52 | 319.1% | -1.64 |
| Peer Median | - | - | 1.15 | -93.4% | -1.64 | |